{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:59:47Z","timestamp":1791140387311,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.clinbiochem.2012.10.012","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T03:01:24Z","timestamp":1350961284000},"page":"480-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Translational proteomics in Alzheimer's disease and related disorders"],"prefix":"10.1016","volume":"46","author":[{"given":"Roberta","family":"Ghidoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Paterlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Benussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0005","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2006-956755","article-title":"Frontotemporal dementia","volume":"27","author":"Graff-Radford","year":"2007","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0025","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/archneur.58.12.1985","article-title":"Current concepts in mild cognitive impairment","volume":"58","author":"Petersen","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1474-4422(03)00262-X","article-title":"Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment","volume":"2","author":"DeCarli","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0040","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0045","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0050","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0085","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","article-title":"Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study","volume":"8","author":"Visser","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jalz.2009.04.1235","article-title":"Markers of Alzheimer's disease in a population attending a memory clinic","volume":"5","author":"Frisoni","year":"2009","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0100","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00415-010-5650-0","article-title":"The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment","volume":"257","author":"Galluzzi","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.21559","article-title":"Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly","volume":"65","author":"Fagan","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0110","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/WNL.0b013e31820af900","article-title":"Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease","volume":"76","author":"Roe","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JAD-2011-110038","article-title":"Amyloid-\u03b242 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment","volume":"26","author":"Rolstad","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.exger.2009.09.008","article-title":"Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects","volume":"45","author":"Cedazo-Minguez","year":"2010","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.exger.2009.10.010","article-title":"Total and phosphorylated tau protein as biological markers of Alzheimer's disease","volume":"45","author":"Hampel","year":"2010","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0130","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer's disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0135","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease","volume":"289","author":"Sunderland","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.exger.2009.06.003","article-title":"Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)","volume":"44","author":"Buerger","year":"2009","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0145","first-page":"986310","article-title":"Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid","volume":"2010","author":"Bjerke","year":"2010","journal-title":"Int J Alzheimers Dis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","article-title":"The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers","volume":"7","author":"Mattsson","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0155","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0160","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0165","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A exanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0170","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp.2010.212225","article-title":"Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review","volume":"82","author":"Seelaar","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0175","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature05016","article-title":"Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17","volume":"442","author":"Baker","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0180","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nature05017","article-title":"Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21","volume":"442","author":"Cruts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0185","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neurobiolaging.2006.10.028","article-title":"A novel deletion in progranulin gene is associated with FTDP-17 and CBS","volume":"29","author":"Benussi","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-007-0237-2","article-title":"Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration","volume":"114","author":"Cairns","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0195","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0200","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.brainres.2012.01.075","article-title":"Losing protein in the brain: the case of progranulin","volume":"1476","author":"Ghidoni","year":"2012","journal-title":"Brain Res"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0205","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1212\/01.wnl.0000325058.10218.fc","article-title":"Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration","volume":"71","author":"Ghidoni","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0210","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ana.21621","article-title":"Serum biomarker for progranulin-associated frontotemporal lobar degeneration","volume":"65","author":"Sleegers","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0215","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/brain\/awn352","article-title":"Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members","volume":"132","author":"Finch","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000333132","article-title":"Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study","volume":"9","author":"Ghidoni","year":"2012","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0225","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/359322a0","article-title":"Amyloid beta-peptide is produced by cultured cells during normal metabolism","volume":"359","author":"Haass","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0230","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1073\/pnas.89.13.6075","article-title":"Beta-amyloid precursor protein cleavage by a membrane-bound protease","volume":"89","author":"Sisodia","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0235","first-page":"697036","article-title":"A window into the heterogeneity of human cerebrospinal fluid A\u03b2 peptides","volume":"2011","author":"Ghidoni","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0240","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.2174\/138161211797416039","article-title":"Novel a\u03b2 isoforms in Alzheimer's disease\u2014their role in diagnosis and treatment","volume":"17","author":"Portelius","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/prca.201100082","article-title":"Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-\u03b2 peptides","volume":"6","author":"Bibl","year":"2012","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0250","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3233\/JAD-2012-111796","article-title":"Aminoterminally truncated and oxidized amyloid-\u03b2 peptides in the cerebrospinal fluid of Alzheimer's disease patients","volume":"29","author":"Bibl","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0255","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3233\/JAD-2009-1142","article-title":"Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides","volume":"18","author":"Ghidoni","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0260","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1750-1326-5-2","article-title":"Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease","volume":"5","author":"Portelius","year":"2010","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0265","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3892\/mmr.2012.774","article-title":"The amyloid-\u03b2 isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease","volume":"5","author":"Portelius","year":"2012","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0270","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/alzrt30","article-title":"A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease","volume":"2","author":"Portelius","year":"2010","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0275","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JAD-2012-120508","article-title":"Amyloid-\u03b21-15\/16 as a marker for \u03b3-secretase inhibition in Alzheimer's disease","volume":"31","author":"Portelius","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0280","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00702-006-0618-z","article-title":"Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations","volume":"114","author":"Bibl","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0285","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00702-012-0801-3","article-title":"Cerebrospinal fluid amyloid-\u03b2 2\u201342 is decreased in Alzheimer's, but not in frontotemporal dementia","volume":"119","author":"Bibl","year":"2012","journal-title":"J Neural Transm"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0290","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00702-006-0537-z","article-title":"CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies","volume":"113","author":"Bibl","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0295","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/1522-2683(200105)22:9<1834::AID-ELPS1834>3.0.CO;2-V","article-title":"Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption\/ionization-time of flight-mass spectrometry","volume":"22","author":"Hesse","year":"2001","journal-title":"Electrophoresis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0300","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00001756-200204160-00015","article-title":"Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients","volume":"13","author":"Davidsson","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0305","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1522-2683(200207)23:14<2247::AID-ELPS2247>3.0.CO;2-M","article-title":"Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease","volume":"23","author":"Choe","year":"2002","journal-title":"Electrophoresis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0310","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","article-title":"Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease","volume":"118","author":"Puchades","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0315","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/pmic.200300470","article-title":"A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease","volume":"3","author":"Carrette","year":"2003","journal-title":"Proteomics"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0320","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1373\/clinchem.2006.078014","article-title":"Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease","volume":"53","author":"Korolainen","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0325","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.21038","article-title":"Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease","volume":"61","author":"Finehout","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0330","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s11064-008-9588-x","article-title":"Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals","volume":"33","author":"Sihlbom","year":"2008","journal-title":"Neurochem Res"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2007.00985.x","article-title":"Clinical proteomics in neurodegenerative disorders","volume":"118","author":"Zetterberg","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0340","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.neurobiolaging.2007.01.011","article-title":"Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease","volume":"29","author":"Simonsen","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0345","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1309\/W01Y0B808EMEH12L","article-title":"CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases","volume":"129","author":"Zhang","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0350","doi-asserted-by":"crossref","first-page":"e16032","DOI":"10.1371\/journal.pone.0016032","article-title":"Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease","volume":"6","author":"Perrin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0355","doi-asserted-by":"crossref","first-page":"e26540","DOI":"10.1371\/journal.pone.0026540","article-title":"Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers","volume":"6","author":"Jahn","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0360","doi-asserted-by":"crossref","first-page":"e18850","DOI":"10.1371\/journal.pone.0018850","article-title":"Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis","volume":"6","author":"Craig-Schapiro","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0365","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","article-title":"Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment","volume":"119","author":"Hu","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0370","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0169-328X(02)00549-1","article-title":"Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins","volume":"109","author":"Davidsson","year":"2002","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0375","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-5956-2-7","article-title":"Validation of a prefractionation method followed by two-dimensional electrophoresis\u2014applied to cerebrospinal fluid proteins from frontotemporal dementia patients","volume":"2","author":"Hansson","year":"2004","journal-title":"Proteome Sci"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0380","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000110576","article-title":"A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia","volume":"24","author":"Simonsen","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0385","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.expneurol.2005.08.002","article-title":"Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF","volume":"196","author":"R\u00fcetschi","year":"2005","journal-title":"Exp Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0390","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","article-title":"Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders","volume":"9","author":"Abdi","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0395","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/1354750X.2010.536995","article-title":"Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias","volume":"16","author":"Abraham","year":"2011","journal-title":"Biomarkers"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0400","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1179\/016164106X98035","article-title":"Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects","volume":"28","author":"Casta\u00f1o","year":"2006","journal-title":"Neurol Res"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0405","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/13547500903108423","article-title":"Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease","volume":"14","author":"Roher","year":"2009","journal-title":"Biomarkers"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0410","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1074\/mcp.M900513-MCP200","article-title":"In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification","volume":"9","author":"Mouton-Barbosa","year":"2010","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0415","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1002\/pmic.200402053","article-title":"Recent advances in blood-related proteomics","volume":"5","author":"Thadikkaran","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0420","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/pmic.201000460","article-title":"Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead","volume":"11","author":"Ray","year":"2011","journal-title":"Proteomics"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0425","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/bmm.09.84","article-title":"Blood-based biomarkers of Alzheimer's disease: challenging but feasible","volume":"4","author":"Thambisetty","year":"2010","journal-title":"Biomark Med"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0430","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ni1078","article-title":"Elaborate interactions between the immune and nervous systems","volume":"5","author":"Steinman","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0435","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0440","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archneurol.2008.530","article-title":"Blood protein signature for the early diagnosis of Alzheimer disease","volume":"66","author":"Britschgi","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0445","doi-asserted-by":"crossref","first-page":"e3111","DOI":"10.1371\/journal.pone.0003111","article-title":"Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease","volume":"3","author":"G\u00f3mez Ravetti","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0450","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.05066.x","article-title":"Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels","volume":"1180","author":"Soares","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.clinbiochem.2012.10.012_bb0455","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archneurol.2010.215","article-title":"A serum protein-based algorithm for the detection of Alzheimer disease","volume":"67","author":"O'Bryant","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0460","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.neurobiolaging.2009.03.011","article-title":"Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease","volume":"32","author":"Marksteiner","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0465","doi-asserted-by":"crossref","first-page":"e34341","DOI":"10.1371\/journal.pone.0034341","article-title":"Alzheimer's Disease Neuroimaging Initiative. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset","volume":"7","author":"Johnstone","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0470","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jprot.2011.04.021","article-title":"Facing challenges in proteomics today and in the coming decade: report of roundtable discussions at the 4th EuPA Scientific Meeting, Portugal, Estoril","volume":"75","author":"Cox","year":"2011","journal-title":"J Proteomics"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0475","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000245156","article-title":"Peripheral cytokines and chemokines in Alzheimer's disease","volume":"28","author":"Lee","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0480","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/brain\/awl279","article-title":"Proteome-based plasma biomarkers for Alzheimer's disease","volume":"129","author":"Hye","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0485","doi-asserted-by":"crossref","first-page":"e28527","DOI":"10.1371\/journal.pone.0028527","article-title":"Plasma biomarkers of brain atrophy in Alzheimer's disease","volume":"6","author":"Thambisetty","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0490","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2012-112012","article-title":"Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study","volume":"30","author":"Zabel","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2011.00001","article-title":"Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases","volume":"3","author":"Ros\u00e9n","year":"2011","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0500","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00401-008-0389-8","article-title":"TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration","volume":"116","author":"Foulds","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0505","series-title":"Biochemical Individuality: The Basis for the Genetotrophic Concept","author":"Williams","year":"1956"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0510","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/clinchem\/16.12.1028","article-title":"Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 3 Physiological and medical implications","volume":"16","author":"Cotlove","year":"1970","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0515","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/clinchem\/16.12.1022","article-title":"Biological and analytic components of variation inlong-term studies of serum constituents in normal subjects.2 Estimating biological components of variation","volume":"16","author":"Harris","year":"1970","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0520","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/clinchem\/16.12.1016","article-title":"Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 1 Objectives, subject selection, laboratory procedures, and estimation of analytic deviation","volume":"16","author":"Williams","year":"1970","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0525","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/clinchem\/17.10.983","article-title":"Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 5 Estimated biological variations in ionized calcium","volume":"17","author":"Harris","year":"1971","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0530","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/clinchem\/17.5.403","article-title":"Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 4 Results of a study design to eliminate long-term analytic deviations","volume":"17","author":"Young","year":"1971","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0535","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/clinchem\/20.12.1535","article-title":"Effects of intraindividual and interindividual variation on appropriate use of normal ranges","volume":"20","author":"Harris","year":"1974","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0540","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neurobiolaging.2004.03.012","article-title":"Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid","volume":"26","author":"Zhang","year":"2005","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0545","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0550","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.wad.0000184005.22611.cc","article-title":"Early-stage and preclinical Alzheimer disease","volume":"19","author":"Morris","year":"2005","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0555","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archneurol.2011.642","article-title":"Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations","volume":"69","author":"Ringman","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0560","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/archneurol.2012.277","article-title":"Plasma signaling proteins in persons at genetic risk for Alzheimer Disease: influence of APOE genotype","volume":"69","author":"Ringman","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0565","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1021\/pr200270z","article-title":"Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease","volume":"10","author":"Ijsselstijn","year":"2011","journal-title":"J Proteome Res"},{"key":"10.1016\/j.clinbiochem.2012.10.012_bb0570","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3233\/JAD-2010-101350","article-title":"Proteome-based plasma markers of brain amyloid-\u03b2 deposition in non-demented older individuals","volume":"22","author":"Thambisetty","year":"2010","journal-title":"J Alzheimers Dis"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201200567X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201200567X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:39:55Z","timestamp":1757864395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991201200567X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S000991201200567X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.10.012","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational proteomics in Alzheimer's disease and related disorders","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}